Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
Authors:
- Annabel H. S. AligAAAnnabel H. S. Alig
- Volker HeinemannVHVolker Heinemann
- Michael GeisslerMGMichael Geissler
- Ludwig Fischer von WeikersthalLWLudwig Fischer von Weikersthal
- Thomas DeckerTDThomas Decker
- Kathrin HeinrichKHKathrin Heinrich
- Swantje HeldSHSwantje Held
- Lena WeissLWLena Weiss
- Laura E. FischerLFLaura E. Fischer
- Nicolas MoosmannNMNicolas Moosmann
- Arndt StahlerASArndt Stahler
- Ivan JelasIJIvan Jelas
Open Access
Abstract
Primary tumor sidedness (left vs. right) has prognostic and predictive impact on anti-EGFR agent efficacy and thus management of metastatic colorectal cancer (mCRC). This analysis evaluates the relevance of primary tumor location (PTL) in RAS/BRAF wild-type mCRC patients, when dividing the colorectal frame into six segments. This pooled analysis, performed on a single-patient basis of five randomized first-line therapy trials, evaluates the impact of exact PTL classification on baseline characteristics, prognosis and prediction of anti-EGFR antibody efficacy by chi-square and log-rank tests, the Kaplan–Meier method, Cox and logistic regressions. The PTL was significantly associated with metastatic spread: liver (p = 0.001), lung (p = 0.047), peritoneal (p < 0.001) and lymph nodes (p = 0.048). A multivariate analysis indicated an impact on anti-EGFR agent efficacy in terms of overall survival depending on the exact primary tumor location: from detrimental in caecal (HR 2.63), rather neutral effects in the ascending colon (HR 1.24), right flexure/transverse colon (HR 0.99) and left flexure/descending colon (HR 0.91) to clear benefit in sigmoid (HR 0.71) and rectal (HR 0.58) primaries. Exact primary tumor location affects anti-EGFR antibody efficacy in a rather continuous than a dichotomous fashion in RAS/BRAF wild-type mCRC patients. This perspective might help to support clinical decisions when anti-EGFR antibodies are considered.Keywords
This publication has 35 references indexed in Scilit:
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal CancerJournal of Clinical Oncology, 2014
- Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut)Anti-Cancer Drugs, 2014
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2013
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line TrialsClinical Cancer Research, 2013
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumGut, 2012
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306Annals of Oncology, 2012
- The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trialInternational Journal of Cancer, 2011
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study GroupJournal of Clinical Oncology, 2011
- Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancerEuropean Journal of Cancer, 2011